The Microcytic Anemia Factor among Pregnancywith Thalassemias: The Preliminary Study at MaesotHospital, Tak Province
The aim of this study was to demonstrate the microcytic anemia factor (MAF) among participants with apparently healthy and pregnant women who attended the screening program for thalassemia and hemoglobinopathies at Maesot Hospital during January 2007 to December 2016. Two thousand and fifty six participants were recruited. Complete blood count and MAF calculated from [Hb*MCV/100] were obtained in all samples. Thalassemia and hemoglobinopathies were evaluated by using DCIP-test and Hb typing by automated Hb analyzer. The result reveals calculated MAF 12.5 ± 1.2 in normal group which was statistically different from that in pregnant women without thalassemia. In pregnant women, MAF in thalassemia were lower than non-thalassemia (5.6-9.1). In Hb E carrier group with Hb E ≥25%, calculated MAF was 9.1 ± 1.1 which was greater than those with Hb E < 25%. In addition, calculated MAF among homozygous Hb EE, Hb H and β-thal/Hb E disease were 6.7 ± 1.1, 5.6 ± 0.7, and 5.9 ± 2.3, respectively. The results demonstrated that calculated MAF among normal and pregnant women were different. It was decreased in thalassemia and more declined according to number of globin gene defects. Therefore, MAF parameter may be applied to predict α-thal 1 following CBC and DCIP testing prior to Hb typing analysis and α-thal 1 DNA analysis.
- There are currently no refbacks.